Perioperative Benzodiazepine Exposure Impacts Risk of New Persistent Benzodiazepine Use Among Patients with Cancer
- PMID: 39733079
- DOI: 10.1245/s10434-024-16788-3
Perioperative Benzodiazepine Exposure Impacts Risk of New Persistent Benzodiazepine Use Among Patients with Cancer
Abstract
Background: Benzodiazepines are the third most misused medication, with many patients having their first exposure during a surgical episode. We sought to characterize factors associated with new persistent benzodiazepine use (NPBU) among patients undergoing cancer surgery.
Patients and methods: Patients who underwent cancer surgery between 2013 and 2021 were identified using the IBM-MarketScan database. NPBU was defined as one prescription filled during the 90-180 days period after surgery by patients who were previously benzodiazepine naïve. The association of variables with perioperative benzodiazepine use and NPBU was assessed using multivariable regression.
Results: Among 34,637 patients with cancer (breast: n = 5460, 15.8%; lung: n = 3479, 10.0%; esophagus: n = 384, 1.1%; gastric: n = 852, 2.5%; liver: n =502, 1.4%; biliary: n = 268, 0.8%; pancreas: n = 1290, 3.7%; colon: n = 10,838, 31.3%; rectum: n = 2566, 7.4%; prostate: n = 8998, 26.0%), most were male (n = 19,687, 56.8%) with a median age of 57 years (IQR 51-61 years). Overall, 8.8% of patients had perioperative benzodiazepine use and 7.5% of patients developed NPBU following surgery. On multivariable analyses, perioperative benzodiazepine exposure (ref. no perioperative exposure: OR 2.00, 95% CI 1.68-2.38) and higher perioperative dose of > 32.0 lorazepam milligram equivalents (LME) (ref. < 10 LME: OR 2.42, 95% CI 2.01-2.92) were independently associated with higher odds of NPBU. Notably, male patients had lower odds of NPBU versus female patients (OR 0.80, 95% CI 0.68-0.94).
Conclusions: Roughly 1 in 13 commercially insured patients developed NPBU following surgery for cancer. Judicious use of benzodiazepines among patients with high risk of misuse can mitigate NPBU to help avoid benzodiazepine-related complications such as overdose or accidental deaths.
Keywords: Chemoradiotherapy; Lorazepam milligram equivalents; Misuse; Prescription drugs; Temporal trends.
© 2024. Society of Surgical Oncology.
Conflict of interest statement
Disclosures: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors declare no funding or financial support. The authors declare no conflict of interest.
References
-
- Khalil M, Woldesenbet S, Munir MM, et al. Long-term health outcomes of new persistent opioid use after gastrointestinal cancer surgery. Ann Surg Oncol. 2024;31(8):5283–92. https://doi.org/10.1245/s10434-024-15435-1 . - DOI - PMC - PubMed
-
- Wilson N. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020. https://doi.org/10.15585/mmwr.mm6911a4 . - DOI - PMC - PubMed
-
- Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95–114. https://doi.org/10.1016/j.drugalcdep.2019.02.033 . - DOI - PMC - PubMed
-
- Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health. 2016;106(4):686–8. https://doi.org/10.2105/AJPH.2016.303061 . - DOI - PMC - PubMed
-
- Peng L, Meeks TW, Blazes CK. Complex persistent benzodiazepine dependence—when benzodiazepine deprescribing goes awry. JAMA Psychiatry. 2022;79(7):639–40. https://doi.org/10.1001/jamapsychiatry.2022.1150 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
